deucravacitinib
nimbus,bms,ventyx
['deucrava', 'psoriasis', 'eve ', 'psoriatic arthritis', 'crohn', 'deucra', 'nimbus', '$vtyx']
deucravacitinib is expecting approval in plaque psoriasis.
it would be a win for the tyk2 field. but tyk2 is not only psoriasis. $vtyx is looking into psoriatic arthritis, crohn s disease and more
nimbus also has tyk2 in clinic.
i believe all will profit from deucrava approval 
#Protein_Degraders, #Synthetic_Biology, #AI_Drug_Development, #CNS, #ACGT are the four DNA bases.